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Summary
With the addition of rituximab and other treatment advances, survival after diffuse large B-cell 
lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged 
as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios 
(SIRs) and 95% confidence intervals (CIs) for SPMs among 23,879 patients who survived at least 
1 year after a first primary DLBCL diagnosed during 1989–2012, compared to the general 
population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk 
of death, also was calculated. We found that the incidence of acute myeloid leukaemia (AML) 
nearly doubled in the post-rituximab era [SIR (95%CI) 4.39 (2.51–7.13) pre- (1989–2000) and 
8.70 (6.62–11.22) post-rituximab (2001–2012)]. Subsequent thyroid cancer was rare pre-
rituximab, but increased substantially after 2001 [0.66 (0.08–2.37) vs. 2.27(1.44–3.41)]. The 5-
year CMI for all SPMs (4.77% pre- vs. 5.41% post-rituximab, P=0.047), AML (0.15% vs. 0.41%, 
P=0.003), thyroid cancer (0.03% vs. 0.15%, P=0.003) and melanoma (0.25% vs. 0.42%, P=0.020) 
were greater in DLBCL patients diagnosed in the post-versus pre-rituximab period. This study 
provides insight into the changing pattern of SPM occurrence after the introduction of rituximab, 
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which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts 
among DLBCL patients.
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Introduction
Introduction of the monoclonal anti-CD20 antibody rituximab in the late 1990’s represents 
one of the most important advances in the treatment of diffuse large B-cell lymphoma 
(DLBCL), followed by a 30% decrease in mortality among DLBCL patients.(Tao, et al 
2014) With patients achieving longer-term survival, management of subsequent primary 
malignancies (SPMs) is an emerging challenge. While rituximab-induced B-cell dysfunction 
and immunodeficiency may lead to increased susceptibility to infections and progression of 
malignancies,(Chapel, et al 2003, Kaplan, et al 2014) there have been few reports of 
rituximab-related secondary cancers after DLBCL,(Aksoy, et al 2011, Cho, et al 2015, 
Fleury, et al 2015, Hua, et al 2015, Pfreundschuh 2006, Solal-Celigny 2006) with the 
exception of two reports of melanoma acceleration after rituximab treatment.(Peuvrel, et al 
2013, Velter, et al 2014) A large Surveillance, Epidemiology, and End Results (SEER) 
analysis reported that DLBCL patients diagnosed 1992–2006 had 11% higher rate of overall 
SPM than the general population, with particularly elevated risks for second primary 
Hodgkin lymphoma (HL) and certain leukaemias.(Morton, et al 2010) However, no 
population-based studies have assessed whether the risk, or patterns, of SPMs changed after 
the introduction of rituximab in 2001.
In this study, we utilized sequential tumour data available from the large and high quality, 
population-based California Cancer Registry (CCR) to describe the incidence of SPMs 
before (1989–2000) and after (2001–2012) the routine use of rituximab was incorporated 
into standard first-line therapy for DLBCL.(Coiffier, et al 1998, Coiffier, et al 2002) We 
report the occurrence of SPMs overall and by cancer type, patient characteristics, use of 
chemotherapy and radiation therapy, and latency period between DLBCL and 
haematological SPMs in order to inform cancer surveillance efforts among DLBCL patients.
Methods
Patients
We identified 25,089 patients of all ages who survived for at least 1 year after diagnosis of a 
first primary DLBCL (International Classification of Diseases-Oncology, 3rd edition [ICD-
O-3] morphology codes 9678–9680, 9684) between the years 1989 and 2012 in California. 
Among these patients, we excluded 1,210 who had evidence of human immunodeficiency 
virus infection or acquired immunodeficiency syndrome (Tao, et al 2014), resulting in a final 
study population of 23,879 DLBCL patients. We obtained information on age at diagnosis, 
race/ethnicity, stage at diagnosis, residential address at diagnosis and initial treatment 
modalities (chemotherapy and radiation therapy) for the first primary DLBCL based on the 
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routinely abstracted medical record. Over the period of our study, the receipt of rituximab 
was not recorded separately from chemotherapy and neither specific chemotherapy regimens 
nor radiation doses were available in the cancer registry. We used a multi-component index 
of neighbourhood socioeconomic status (SES) based on patients’ residential census-block 
group at diagnosis.(Tao, et al 2014) The index is grouped into quintiles, based on the 
distribution of SES among all census block groups in California. We also obtained 
information regarding the occurrence of subsequent invasive cancers that developed at least 
1 year after the initial DLBCL diagnosis, as done previously (Lam, et al 2015, Morton, et al 
2010). All subsequent cases of non-Hodgkin lymphoma, lymphocytic leukaemia and Kaposi 
sarcoma were excluded from overall subsequent malignancy risk estimates because of the 
difficulty of distinguishing disease progression from the primary DLBCL.
The addition of rituximab to conventional chemotherapy started in the late 1990’s(Coiffier 
2007, Molina 2008) and became a consensus standard therapy after 2002.(Coiffier, et al 
2009) Survival data on rituximab use in combination with chemotherapy for treatment of 
DLBCL were first presented in 2000 and its use was rapidly adopted in clinical practice.
(Flowers, et al 2012, Sinha, et al 2012) Therefore 2001 was considered the beginning of the 
rituximab era. Patients in the pre- and post-rituximab treatment era were followed for the 
same period of time (study end date 31 December 2000 for patients diagnosed in pre-
rituximab era and 31 December 2012 for patients diagnosed post-rituximab). All study 
protocols were overseen by the Institutional Review Board of the Cancer Prevention Institute 
of California.
Statistical Analysis
SEER*Stat version 8.2.1 (National Cancer Institute, Bethesda, MD) was used to calculate 
standardized incidence ratios (SIRs) and the corresponding 95% confidence intervals (CIs) 
for DLBCL patients by comparing these patients’ subsequent cancer experience with the 
number of cancers that would be expected based on the 5-year age-, sex-, calendar year- and 
race/ethnicity-specific incidence rates for the general California population. SEER*Stat 
calculates observed (O) and expected (E) numbers of SPMs, the latter based on California 
state-wide cancer incidence rates applied to the total person-years of follow-up, weighted 
appropriately for cohort distributions of race and/or ethnicity, attained age, and attained 
calendar year. The SIR is a relative risk measure representing the ratio of O to E (O/E). We 
calculated SIRs for all invasive cancers and by invasive cancer type as well as by age group 
at diagnosis (<65, ≥65 years), sex, race/ethnicity, initial treatment, neighbourhood SES and 
latency. These age groups were chosen because of previously observed differences in 
survival patterns by age before and after the introduction of rituximab.(Tao, et al 2014) 
Statistics with fewer than three cases are not shown for privacy reasons.
The cumulative incidence of developing a SPM after the diagnosis of DLBCL was 
calculated using the life-test procedure for evaluating the Kaplan-Meier survival function 
using SAS software version 9.3 (SAS Institute, Cary, NC). Death was accounted for as a 
competing risk in these analyses. Person-years of observation were compiled from date of 
the first primary DLBCL diagnosis to the date of diagnosis of a SPM, the study cut-off date 
for each treatment era, or the date of death (before each study cut-off date), whichever 
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occurred first. Gray’s K-sample test statistic was used to determine whether the difference in 
cumulative incidence of SPM was statistically significant (P-values that were <0.05) before 
and after the introduction of rituximab (Gray 1988) for all DLBCL patients, for all 
subsequent cancers and by SPM cancer site.
Results
Among 23,879 DLBCL patients in California who survived at least one year after diagnosis, 
the median (95% CI) person-years of follow-up was 3.61 (3.52–3.70) and 4.53 (4.43–4.61) 
for patients diagnosed before and after 2001, respectively. The mean age (±standard 
deviation) was 59.0 (±17.6) and 60.4 (±17.0) years for patients diagnosed in the two 
treatment eras, respectively. Most patients were non-Hispanic white, but, reflecting changes 
in the California population over time, the proportion of Hispanic and Asian patients 
increased in the later era (Table I). Relative to the pre-rituximab era, DLBCL patients 
diagnosed after 2001 were somewhat more likely to receive chemotherapy and less likely to 
receive radiation therapy (Table I), patterns that were similar in patients diagnosed with both 
localized/regional and advanced disease (data not shown).
Subsequent primary solid tumours were diagnosed in a total of 495 patients diagnosed in the 
pre-rituximab era (compared with 430 expected in the general California population, SIR 
1.15, 95%CI 1.05–1.26), and in 773 in the post-rituximab era (compared with 713 expected 
in the general population, SIR 1.08, 95%CI 1.01–1.16; Table II). Subsequent thyroid cancers 
were rare in DLBCL survivors in the pre-rituximab era, but rates increased considerably 
during the post-rituximab era (SIR 2.27, 95%CI 1.44–3.41), regardless of radiation therapy 
use for the treatment of their DLBCL (SIR 2.13, 95%CI 0.78–4.63 for patients with 
radiation therapy and SIR 2.33, 95%CI 1.36–3.96 for patients without radiation therapy; 
Supplementary Table). By contrast, we found higher risks of subsequent primary colorectal 
and breast cancers in patients diagnosed in the pre-rituximab era (borderline significance), 
although the risks were comparable to the underlying population in rituximab era. The SIRs 
for lung cancer, liver cancer and melanoma were comparable in the pre- and post-rituximab 
era. For subsequent primary tumours, we did not observe notable differences in SIRs in each 
treatment era by age group at diagnosis, sex, race/ethnicity, initial treatment, neighbourhood 
SES or in latency (Supplementary Table). SIRs appeared to be either similar by stage at 
DLBCL diagnosis or more pronounced for DLBCL patients diagnosed with advanced 
(versus localized/ regional) stage disease (Supplementary Table).
Table III shows that rates of acute myeloid leukaemia (AML) among DLBCL patients 
doubled in the post-rituximab era (SIR 4.39, 95%CI 2.51–7.13 pre- vs. SIR 8.70, 95%CI 
6.62–11.22 post-rituximab). Unlike patients diagnosed in the pre-rituximab era, DLBCL 
patients diagnosed in the post-rituximab era had persistently high rates of AML over time, 
particularly after 5 years (SIR 10.42, 95%CI 5.38–18.20 for ≥7 years from DLBCL 
diagnosis). For HL, the elevated rate persisted in both treatment eras, but was slightly lower 
in the post-rituximab era (SIR 10.38, 95%CI 5.36–18.13 pre- vs. SIR 7.99, 95%CI 4.57–
12.98 post-rituximab); this difference was not statistically significant. For subsequent 
primary AML and HL, we did not observe notable differences in SIRs by age group at 
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DLBCL diagnosis, stage at DLBCL diagnosis, sex, race/ethnicity, or neighbourhood SES 
(Supplementary Table).
Overall, the cumulative incidence of all subsequent malignancies was greater in DLBCL 
patients diagnosed in the post-rituximab era than those diagnosed in the pre-rituximab era 
(cumulative incidence at 5- and 10-year after diagnosis was 4.77% and 9.67% in the pre-
rituximab and 5.41% and 10.47% in the post-rituximab period, respectively; P= 0.047, Table 
IV and Fig 1). The 5-year cumulative incidence of AML (0.15% pre- vs. 0.41% post-
rituximab, P=0.003), thyroid cancer (0.03% pre- vs. 0.15% post-rituximab, P=0.003) and 
melanoma (0.25% pre- vs. 0.42% post-rituximab, P=0.020), were significantly greater in 
DLBCL patients diagnosed in the post-versus pre-rituximab period (Table IV and Fig 2). No 
differences in the cumulative incidence of other cancers in the post-versus pre-rituximab 
period were observed (Table IV).
Discussion
To our knowledge, this is the first population-based study to describe the occurrence of 
SPMs in DLBCL patients before and after the common use of rituximab in the United 
States. Our findings suggest that DLBCL patients were more likely to develop a subsequent 
melanoma, thyroid cancer or AML in the post-rituximab than the pre-rituximab era. Further, 
we observed elevated rates of subsequent HL, lung cancer and liver cancer among DLBCL 
survivors as compared to the general population in the post-rituximab era. Overall, this study 
provides insight on the changing pattern of SPM occurrence after the introduction of 
rituximab, information that can guide cancer surveillance efforts among DLBCL patients.
Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed in 
more than 95% of normal and malignant B-cells, inducing complement-mediated and 
antibody-dependent cellular cytotoxicity.(Plosker and Figgitt 2003) In contrast to traditional 
chemotherapy agents, rituximab presents a favourable toxicity profile with the most 
frequently observed adverse events being infection, fever, and neutropenia (Neves and Kwok 
2015). On the other hand, the prolonged duration of rituximab-induced B-cell depletion and 
T-cell inactivation might cause impaired immune-surveillance and the prolonged 
immunosuppressive state could provoke the development and progression of certain SPMs.
(Aksoy, et al 2011, Tan and Coussens 2007) Furthermore, the use of rituximab has 
dramatically improved DLBCL outcomes,(Komrokji, et al 2011, Tao, et al 2014) with 
patients now surviving long after treatment. As a result, host susceptibility, shared 
aetiological elements, additional treatments and other exposures, and enhanced clinical 
surveillance(Morton, et al 2014) may lead to the occurrence of SPMs, an important cause of 
morbidity and mortality.(Travis, et al 1993, Tward, et al 2006)
Our study is the first to identify heightened risk for subsequent thyroid cancer in DLBCL 
patients diagnosed in the rituximab treatment era. While increased rates of incidental 
detection with more sensitive imaging tools and more frequent use of ultrasound could 
explain some of the incidence increase, we would also expect more sensitive imaging to 
detect other solid tumours, which we did not observe. Multiple studies have found positive 
associations between radiation therapy, but not chemotherapy (Meadows, et al 2009), and 
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the risk for subsequent thyroid cancer after a diagnosis of head and neck cancer, AML, or 
HL,(Meadows, et al 2009, Ron, et al 1995, Tolisano, et al 2015) and some studies have 
described thyroid disorders associated with rituximab use (Hartmann 2015, Raterman, et al 
2009). Our findings suggest that the increased risk of thyroid cancer post-rituximab occurred 
in DLBCL patients with either localized/regional or advanced stage disease regardless of 
radiation therapy use. Further studies, particularly those focused on stimulation of thyroid 
function and risk of subsequent thyroid cancer after rituximab therapy, are warranted.
There is suggestive prior evidence for an association between rituximab-containing regimens 
and risk of secondary AML (Lam, et al 2016, Zhao, et al 2012, Zhou, et al 2012), but studies 
investigating the risk of SPMs during time periods when monoclonal antibodies were used 
widely for treatment of haematological malignancies are sparse.(Baldo 2013) Significant 
excesses of AML have been reported among lymphoma patients, and our SIR of 4.39 for 
secondary AML in the pre-rituximab era was very close to the SIRs reported in two SEER 
reports [4.83(Morton, et al 2010) and 4.96(Travis, et al 1993)]. However, it is important to 
note that the risk of AML was doubled (SIR 8.70) after the introduction of rituximab for 
DLBCL treatment. Rituximab-related immunodeficiency may last several years (Plosker and 
Figgitt 2003), which is consistent with our finding of the excess risk of AML over time. In 
the post-rituximab era, we observed an increase in the cumulative incidence of AML within 
5 years of DLBCL diagnosis. This time-period for the onset of AML following treatment 
has been more commonly associated with topoisomerase II inhibitor use.(Allan and Travis 
2005, Leone, et al 2001) These data raise the possibility that this risk may be potentiated by 
rituximab. A plateau in the cumulative incidence of AML was observed between 5 and 7 
years after DLBCL, the time-period dominated by alkylator- or radiation therapy-related 
AML,(Allan and Travis 2005) suggesting that the impact of these therapies may not differ 
with the use of rituximab. It was followed by an increase in the cumulative incidence again 
after 7 years, which may be an ongoing late effect of alkylating agents or radiation.(Allan 
and Travis 2005, Leone, et al 2001) However, without details of DLBCL therapy available, 
we were unable to consider these specific treatment associations in this study.
Increased risks of malignant melanoma were previously recognized in patients with non-
Hodgkin lymphoma subtypes other than DLBCL(Lam, et al 2015, Morton, et al 2010, 
Travis, et al 1993) treated with fludarabine-containing chemotherapy (with or without 
rituximab), highlighting the role of defective B-cell and T-cell function in some subtypes of 
lymphocytic malignancies.(Anderson, et al 1981, Fisher, et al 1980) We found an overall 
similar risk of melanoma in DLBCL patients compared with the general California 
population in both treatment eras. However, among DLBCL patients, the cumulative 
incidence or frequency of melanoma at specific time-points increased significantly in the 
post-rituximab treatment era, suggesting an association between immune perturbation and 
risk of melanoma in the context of prolonged survival in DLBCL patients and increased 
rates of melanoma in the general population of California. In addition, we found 
substantially higher risks of subsequent HL after DLBCL in both treatment eras, consistent 
with previous studies. (Hemminki, et al 2008, Moser, et al 2006, Tward, et al 2006)
Our study is unique in that it had a population-based design with sufficient size and 
statistical power to detect significant changes in SPM incidence in DLBCL survivors 
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diagnosed before and after the introduction of rituximab. A strength of our analysis is that 
we provide both SIR and cumulative incidence estimates, the latter of which takes into 
account the competing risk of death, to determine differences in the occurrence of SPM 
between the two time periods. Unlike clinical studies, this study was not subject to 
predefined inclusion criteria or treatment in specific hospitals/centres, and population-based 
cancer registries have low levels of pathological misclassification for cancers; thus, the 
results of our analyses are generalizable to the larger DLBCL patient population. One caveat 
that warrants consideration is the lack of available registry information on DLBCL-specific 
measurements, such as cell of origin, performance status and treatment details (i.e., use of 
rituximab and types/doses of chemotherapy or radiation), which limited our ability to 
characterize factors associated with SPMs. We also lacked treatment data beyond the first 
course of therapy, including potential additional treatment exposures due to relapse, 
resulting in the potential for treatment under-ascertainment. Furthermore, we did not have 
any other individual patient information regarding SPM risk factors (e.g., smoking history 
for lung cancer) that would allow us to rule out influences of patient selection on our results. 
Additional cohort studies, preferably involving large databases with more detailed medical 
history, are needed to evaluate the association of rituximab receipt with SPMs in other 
DLBCL or non-Hodgkin lymphoma survivor populations to confirm these findings.
In conclusion, we found a substantially elevated incidence of subsequent primary melanoma, 
thyroid cancer and AML in DLBCL patients diagnosed after the introduction of rituximab. 
Rates of subsequent HL, lung cancer and liver cancer were significantly elevated regardless 
of treatment era. To clarify the role of rituximab and other treatments on the risk of specific 
SPMs over time, further investigations should incorporate details of cancer treatment and 
other patient and clinical factors when evaluating factors associated with SPMs. The 
changing pattern of SPM occurrence before and after rituximab observed in our study can 
potentially elucidate the aetiology of SPMs and guide cancer surveillance efforts among 
DLBCL patients diagnosed in the modern treatment era, a growing patient population that is 
living longer.
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Cumulative incidence of all subsequent primary malignancies for patients surviving at least 
1 year after a first diagnosis of diffuse large B-cell lymphoma (DLBCL) by treatment era, 
California, 1989–2012
The vertical axis represents cumulative incidence; the horizontal axis represents time in 
years after DLBCL diagnosis. Pre-rituximab treatment era, 1989–2000 (dotted black line) 
and post-rituximab treatment era, 2001–2012 (solid black line).
Tao et al. Page 11














Cumulative incidence of selected subsequent primary malignancies for patients surviving at 
least 1 year after a first diagnosis of diffuse large B-cell lymphoma by treatment era, 
California, 1989–2012
The vertical axis represents cumulative incidence; the horizontal axis represents time in 
years after DLBCL diagnosis. Pre-rituximab treatment era, 1989–2000 (dotted black line) 
and post-rituximab treatment era, 2001–2012 (solid black line).
Tao et al. Page 12






















































































































































































































































































































































































































































































































































































































































































































































































































































Tao et al. Page 15
Table II
Observed incident cases (O) and standardized incidence ratios (SIR) with 95% confidence intervals (CIs) of 
selected subsequent primary solid tumours after an initial diagnosis of diffuse large B-cell lymphoma by 
treatment era, California, 1989–2012
Site of the subsequent primary solid tumour Pre-rituximab (1989–2000) Post-rituximab (2001–2012)
O SIR (95% CIs) O SIR (95% CIs)
All solid tumours 495 1.15 (1.05–1.26) 773 1.08 (1.01–1.16)
Lung 88 1.25 (1.00–1.54) 129 1.23 (1.03–1.46)
Prostate 88 0.94 (0.75–1.16) 121 0.87 (0.72–1.04)
Breast 69 1.25 (0.98–1.59) 76 0.84 (0.66–1.05)
Colorectal 59 1.28 (0.97–1.65) 64 1.00 (0.77–1.27)
Urinary bladder 25 1.01 (0.65–1.49) 51 1.14 (0.85–1.50)
Melanoma of the skin 18 1.22 (0.72–1.93) 50 1.23 (0.91–1.62)
Head and neck 15 0.98 (0.55–1.61) 31 1.26 (0.86–1.79)
Liver 10 1.42 (0.68–2.62) 30 1.66 (1.12–2.37)
Pancreas 15 1.26 (0.71–2.08) 22 0.93 (0.59–1.41)
Kidney 6 0.60 (0.22–1.32) 23 0.95 (0.60–1.42)
Thyroid <3 0.66 (0.08–2.37) 23 2.27 (1.44–3.41)
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